Evidence map›Paper›PMID 7889536›Full record

ArticleCell biophysics

pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.

M Correale, I Abbate, A Paradiso, F Schittulli, C D Dragone, T Tedone, G Gargano, A M Catino, M D Musci, M De Lena

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biophysics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

M CorrealeRIA Laboratory, Oncology Institute of Bari, Italy.
I Abbate
A Paradiso
F Schittulli
C D Dragone
T Tedone
G Gargano
A M Catino
M D Musci
M De Lena
Radiation Oncology Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.

Indexed as

Antibodies, MonoclonalBiomarkersNeoplasm ProteinsProteinsAdultAgedAged, 80 and overBreast NeoplasmsCarcinomaCytosolEstrogensFemaleHumansImmunoradiometric AssayMiddle AgedMultiple Chemical SensitivityAntibodies, MonoclonalBiomarkersEstrogensNeoplasm ProteinsProteinsReceptors, EstrogenReceptors, ProgesteroneTFF1 protein, humanTrefoil Factor-1Tumor Suppressor Proteins

Identifiers

PMID7889536
OpenAlexW1987528752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.